Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Oct 28, 2021; 27(40): 6861-6873
Published online Oct 28, 2021. doi: 10.3748/wjg.v27.i40.6861
Management of hepatitis B and C in special population
Anand V Kulkarni, Nageshwar Reddy Duvvuru
Anand V Kulkarni, Department of Hepatology, Asian Institute of Gastroenterology, Hyderabad 500032, Telangana, India
Nageshwar Reddy Duvvuru, Department of Gastroenterology, Asian Institute of Gastroenterology, Hyderabad 500032, Telanagana, India
Author contributions: Kulkarni AV and Duvvuru NR made the study concept; Kulkarni AV did the initial drafting and DNR critically assessed and edited the manuscript; all authors approved the final manuscript.
Conflict-of-interest statement: The authors declare no conflicts of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
Corresponding author: Anand V Kulkarni, MD, Consultant Physician-Scientist, Department of Hepatology, Asian Institute of Gastroenterology, 6-3-661, Somajiguda, Hyderabad 500032, Telangana, India.
Received: February 22, 2021
Peer-review started: February 22, 2021
First decision: May 13, 2021
Revised: May 30, 2021
Accepted: September 14, 2021
Article in press: September 14, 2021
Published online: October 28, 2021
Core Tip

Core Tip: Hepatitis B and hepatitis C are leading causes of liver disease and pose significant burdens on healthcare and the economy, especially in developing countries. The management of chronic hepatitis B and C in special populations is less known. In this review, we discuss the indications, timing of treatment, and safety of drugs in special populations infected with hepatitis B or C. The special populations discussed herein are those with chronic kidney disease, pregnant women, coinfected patients, healthcare workers, and patients undergoing chemotherapy.